CSI Market
Sign In | Register

Proqr Therapeutics N v (PRQR) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access PRQR Annual Income Statement →
The data below summarizes Proqr Therapeutics N v's income statement results from Dec 31 2024 to Dec 31 2025, enabling period-by-period comparison of operating performance.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
Q4 2025 		0 0 0 (Dec 31 2024)
Revenues
Revenue From Contracts With Customers17.81
Total Revenue17.81
Costs & Expenses
Gross Profit17.81
Selling, Administration, Marketing16.87
Research and Development Expense50.10
Other Operating Expense / -Income-0.49
Total operating costs including COS66.47
Operating income / -loss-48.66
Net Interest Expense / -Income0.00
Other loss / -income-1.43
Total costs & expenses65.04
Income & Taxes
Income / -loss before income taxes-47.22
Income taxes expenses / -benefit0.02
Income after income taxes-47.25
Income / -loss from continuing operations-47.25
Net income / -loss-47.25
Income / -loss to shareholder-10.39
EBIT-47.22
EBITD-44.20
EBITDA-44.20
Earnings Per Share
Basic EPS (excl. extra items)-0.08
Basic Net EPS-0.08
Basic shares outstanding (Mill. of Units)105.33
Diluted Net EPS-0.08
Diluted average shares (Mill. of Units)105.33
4 historic quarters locked

Sign in to unlock the full Proqr Therapeutics N v income statement history.

Sign In Create Free Account

About PRQR Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.